Conference Material
|
Slide Presentation
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
Solomos A,
Musa AM,
Mbui J,
Mohammed R,
Olobo J,
Ritmeijer KKD,
Alcoba G,
Muthoni Ouattara G,
Egondi T,
Nakanwagi P,
Omollo T,
Wasunna M,
Alvar J,
Alves F
View HTML
View PDF
Share
Download
Download
View PDF
Share
Similar Content
Abstract
|
Abstract
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
2023 June 07 • MSF Scientific Day International 2023
Video
|
Video
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
2023 June 07 • MSF Scientific Day International 2023
Loading...
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial | Conference Material / Slide Presentation | MSF Science Portal
Countries
Ethiopia
Kenya
Uganda
Sudan
Subject Area
pediatrics
neglected tropical diseases
kala azar
leishmaniasis
Languages
English
DOI
10.57740/81jj-tz57
Published Date
07 Jun 2023
Conference
MSF Scientific Day International 2023
Linked Content
Conference Material
|
Abstract
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
2023 June 07 • MSF Scientific Day International 2023
Conference Material
|
Video
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
2023 June 07 • MSF Scientific Day International 2023
